Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation

Anti-Cancer Drug Design

Volumn 11, Issue 5, 1996, Pages 351-365

  Seymour, L W ^a   Soyez, H ^b   De Marre, A ^b   Shoaibi, M A ^a   Schacht, E H ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Drug targeting; Mitomycin C; Poly N (2 hydroxyethyl) L glutamine ; Soluble polymers

Indexed keywords

ANTINEOPLASTIC AGENT; AZIRIDINE; GLUTAMINE DERIVATIVE; LYSOSOME ENZYME; MITOMYCIN C; MITOMYCIN C DERIVATIVE; NITROGEN; PRODRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG STABILITY; DRUG TARGETING; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG STABILITY; LEUKEMIA L1210; LEUKEMIA P388; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MITOMYCIN; MITOMYCINS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0030057143     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. COBB, L.M., CONNORS, T.A., ELSON, L.A., KHAN, H.A., MITCHLEY, B.C.V., ROSS, W.C.J. & WHISSON, M.E. (1969). 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): a potent and selective inhibitor of growth of the Walker carcinoma 256. Biochemical Pharmacology, 18, 1519.
2. CONNORS, T.A. (1986). Prodrugs in cancer therapy. Xenobiotica, 16, 975.
3. CONNORS, T.A. & KNOX, R.J. (1995). Prodrugs in cancer therapy. Stem Cells, 13, 501.
4. DE MARRE, A., SOYEZ, H. & SCHACHT, E.H. (1994a). Synthesis of macromolecular mitomycin C derivatives. Journal of Controlled Release, 32, 129.
5. DE MARRE, A., SEYMOUR, L.W. & SCHACHT, E.H. (1994b). Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives. Journal of Controlled Release, 31, 89.
6. DE MARRE, A., SOYEZ, H., SCHACHT, E.H., SHOAIBI, M.A., SEYMOUR, L.W. & RIHOVA, B. (1995). Synthesis and evaluation of macromolecular prodrugs of mitomycin C. Journal of Controlled Release, 36, 87.
7. DILLMAN, R.O. (1994). Monoclonal antibodies as tumor therapy - clinical evidence in favour of their potential usefulness. Clinical Immunotherapeutics, 2, 206.
8. DUNCAN, R., SEYMOUR, L.W., O'HARE, K.B., FLANAGAN, P.A., WEDGE, S.R., HUME, I.C., ULBRICH, K., STROHALM, J., SUBR, V., SPREAFICO, F., GRANDI, M., RIPAMONTI, M., FARAO, M. & SUARATO, A.J. (1992). Preclinical evaluation of polymer-bound doxorubicin. Journal of Controlled Release, 19, 331.
9. DVORAK, H.F. (1986). Tumours - wounds that do not heal. New England Journal of Medicine, 315, 1650.
10. HASHIDA, M. & TAKAKURA, Y. (1994). Pharmacokinetics in design of polymeric drug delivery systems. Journal of Controlled Release, 31, 163.
11. MAEDA, H., SEYMOUR, L.W. & MIYAMOTO, Y. (1992). Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry, 3, 351.
12. MATSUMURA, Y. & MAEDA, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Research, 46, 6387.
13. SEYMOUR, L.W. (1992). Passive tumour-targeting of soluble macromolecules and drug conjugates. Critical Reviews in Therapeutic Drug Carrier Systems, 9, 135.
14. SEYMOUR, L.W. (1994). Soluble polymers for lectin-mediated drug targeting. Advanced Drug Delivery Reviews, 14, 89.
15. SEYMOUR, L.W., ULBRICH, K., STEYGER, P.S., BRERETON, M., SUBR, V., STROHALM, J. & DUNCAN, R. (1994). Tumour tropism and anticancer efficacy of polymer-based anthracycline prodrugs. British Journal of Cancer, 70, 636.
16. SEYMOUR, L.W., MIYAMOTO, Y., MAEDA, H., BRERETON, M., STROHALM, J., ULBRICH, K. & DUNCAN, R. (1995). Influence of molecular size on passive tumour accumulation of soluble macromolecular drug carriers. European Journal of Cancer, 31, 766.
17. SGOURAS, D. & DUNCAN, R. (1990). Methods for evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use. 1. Use of the tetrazolium-based (MTT) colourimetric assay as a preliminary screen for in vitro cytotoxicity. Journal of Materials Science: Materials in Medicine, 1, 61.
18. SOYEZ, H., SCHACHT, E.H., DE MARRE, A. & SEYMOUR, L.W. (1995). Polymeric prodrugs of Mitomycin C. Proceedings of the 5th Dresden Polymer Discussion, 1, 159.
19. STEYGER, P., BABAN, D.F., BRERETON, M., ULBRICH, K. & SEYMOUR, L.W. (1996). Intratumoural distribution as a determinant of tumour responsiveness to therapy using polymer-based macromolecular prodrugs. Journal of Controlled Release, 39, 35.
20. TOKUNAGA, Y., IWASA, T., FUJISAKA, J., SAWAI, S. & KAGAYAMA, A. (1988). Liposomal sustained release delivery systems for intravenous injection. 3. Antitumour activity of lipophilic mitomycin C prodrug-bearing liposomes. Chemical and Pharmaceutical Bulletin, 36, 3365.
21. TROUET, A. (1974). Isolation of rat liver lysosomal enzymes. Methods in Enzymology, 31, 323.